AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36449275 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined nudge
Number of subjects: 4131
Study 33106286 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab 140 mg
Number of subjects: 962
Study 33106286 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab 210 mg
Number of subjects: 962
Study 33106286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 962
Study 33106286 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab (both doses)
Number of subjects: 962
Study 36305424 — intervention group
Group type: EXPERIMENTAL
Intervention: GAN2D
Number of subjects: 206
Study 36305424 — intervention group
Group type: EXPERIMENTAL
Intervention: GAN3D
Number of subjects: 206
Study 36305424 — intervention group
Group type: EXPERIMENTAL
Intervention: SCT images (both GAN2D and GAN3D)
Number of subjects: 206
Study 33441350 — intervention group
Group type: EXPERIMENTAL
Intervention: D-mannose powder daily for 6 months
Number of subjects: 508
Study 33441350 — intervention group
Group type: COMPARATOR
Intervention: Placebo powder daily for 6 months
Number of subjects: 508
Study 35953331 — intervention group
Group type: EXPERIMENTAL
Intervention: FRIL (20 μg)
Number of subjects: 20
Study 35953331 — intervention group
Group type: EXPERIMENTAL
Intervention: CTB-ACE2 (0.925 μg)
Number of subjects: 20
Study 35953331 — intervention group
Group type: EXPERIMENTAL
Intervention: CTB-ACE2 gum powder
Number of subjects: 20
Study 35953331 — intervention group
Group type: EXPERIMENTAL
Intervention: FRIL (50-100 ng)
Number of subjects: 20
Study 35953331 — intervention group
Group type: EXPERIMENTAL
Intervention: FRIL gum
Number of subjects: 20
Study 35953331 — intervention group
Group type: COMPARATOR
Intervention: CTB-ACE2/placebo gum
Number of subjects: 20
Study 33181049 — intervention group
Group type: EXPERIMENTAL
Intervention: Brexanolone (BRX)
Number of subjects: 209
Study 33181049 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 209
Study 34189032 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm acupuncture with silver needle (SvN) at above 43°C
Number of subjects: 159
Study 34189032 — intervention group
Group type: COMPARATOR
Intervention: Warm acupuncture with stainless steel needle (SSN) at above 40°C
Number of subjects: 159
Study 34189032 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm acupuncture with silver needle (SvN)
Number of subjects: 159
Study 34189032 — intervention group
Group type: COMPARATOR
Intervention: Warm acupuncture with stainless steel needle (SSN)
Number of subjects: 159
Study 34256319 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-escalated intensity-modulated radiotherapy (DE-IMRT)
Number of subjects: 276
Study 34256319 — intervention group
Group type: COMPARATOR
Intervention: Standard dose intensity-modulated radiotherapy (ST-IMRT)
Number of subjects: 276
Study 34256319 — intervention group
Group type: EXPERIMENTAL
Intervention: DE-IMRT
Number of subjects: 276
Study 34256319 — intervention group
Group type: COMPARATOR
Intervention: ST-IMRT
Number of subjects: 276
Study 34256319 — intervention group
Group type: EXPERIMENTAL
Intervention: DE-IMRT and ST-IMRT
Number of subjects: 276
Study 34843302 — intervention group
Group type: EXPERIMENTAL
Intervention: Social connectedness intervention
Number of subjects: 416
Study 34843302 — intervention group
Group type: COMPARATOR
Intervention: Passive control group
Number of subjects: 416
Study 34843302 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 416
Study 35802773 — intervention group
Group type: EXPERIMENTAL
Intervention: depression label
Number of subjects: 676
Study 35802773 — intervention group
Group type: EXPERIMENTAL
Intervention: clinical psychologist recommendation
Number of subjects: 676
Study 35802773 — intervention group
Group type: EXPERIMENTAL
Intervention: burnout label
Number of subjects: 676
Study 35802773 — intervention group
Group type: EXPERIMENTAL
Intervention: mind coach recommendation
Number of subjects: 676
Study 35802773 — intervention group
Group type: COMPARATOR
Intervention: no label (control)
Number of subjects: 676
Study 34765049 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese and T2DM (OD) group
Number of subjects: 280
Study 34765049 — intervention group
Group type: COMPARATOR
Intervention: Healthy and lean (HL) group
Number of subjects: 280
Study 34765049 — intervention group
Group type: EXPERIMENTAL
Intervention: All subjects
Number of subjects: 280
Study 34002559 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (filiform needling and tongue picking acupuncture)
Number of subjects: 56
Study 34002559 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment and swallowing function rehabilitation training (Control)
Number of subjects: 56
Study 32149745 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical arthrodesis with plate fixation
Number of subjects: 40
Study 32149745 — intervention group
Group type: COMPARATOR
Intervention: Cervical arthroplasty
Number of subjects: 40
Study 32149745 — intervention group
Group type: EXPERIMENTAL
Intervention: High-grade ALOD
Number of subjects: 40
Study 32149745 — intervention group
Group type: COMPARATOR
Intervention: Low-grade ALOD
Number of subjects: 40
Study 35113861 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth peer mentors (YPMs) trained and hired by Project YES!
Number of subjects: 276
Study 33308810 — intervention group
Group type: EXPERIMENTAL
Intervention: High-velocity, low-load resistance exercise once weekly (HVLL1)
Number of subjects: 40
Study 33308810 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-velocity, high-load resistance exercise once weekly (LVHL1)
Number of subjects: 40
Study 33308810 — intervention group
Group type: EXPERIMENTAL
Intervention: High-velocity, low-load resistance exercise twice weekly (HVLL2)
Number of subjects: 40
Study 33308810 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-velocity, high-load resistance exercise twice weekly (LVHL2)
Number of subjects: 40
Study 33308810 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-velocity, high-load resistance exercise (LVHL)
Number of subjects: 40
Study 36039547 — intervention group
Group type: EXPERIMENTAL
Intervention: Group assertive training
Number of subjects: 50
Study 36039547 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 50
Study 34428360 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth CBT‐I
Number of subjects: 60
Study 34428360 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person CBT‐I
Number of subjects: 60
Study 34428360 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 60
Study 35639792 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cholecalciferol (400,000 IU)
Number of subjects: 254
Study 35639792 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose cholecalciferol (50,000 IU)
Number of subjects: 254
Study 34108081 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglycosides administered in a predialysis schedule
Number of subjects: 206
Study 34108081 — intervention group
Group type: COMPARATOR
Intervention: Aminoglycosides administered in a postdialysis schedule
Number of subjects: 206
Study 34108081 — intervention group
Group type: EXPERIMENTAL
Intervention: Predialysis schedule
Number of subjects: 206
Study 34108081 — intervention group
Group type: COMPARATOR
Intervention: Postdialysis schedule
Number of subjects: 206
Study 33225600 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported pain management
Number of subjects: 655
Study 33225600 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of pain management 'other' than analgesia
Number of subjects: 655
Study 33225600 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of oral analgesia
Number of subjects: 655
Study 33225600 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of 'any' analgesia
Number of subjects: 655
Study 32558298 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine prophylaxis
Number of subjects: 0
Study 32558298 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no colchicine prophylaxis)
Number of subjects: 0
Study 32558298 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine prophylaxis (in Australia)
Number of subjects: 0
Study 32558298 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in Australia)
Number of subjects: 0
Study 37744071 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental PPE (short-sleeved gowns with hand and arm hygiene)
Number of subjects: 85
Study 37744071 — intervention group
Group type: COMPARATOR
Intervention: Control PPE (long-sleeved gowns)
Number of subjects: 85
Study 37744071 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental PPE
Number of subjects: 85
Study 37744071 — intervention group
Group type: COMPARATOR
Intervention: Control PPE
Number of subjects: 85
Study 33309574 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafamidis
Number of subjects: 441
Study 33309574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 441
Study 35001885 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoimmune disorders (AD)
Number of subjects: 243
Study 35001885 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFR polymorphisms
Number of subjects: 243
Study 35001885 — intervention group
Group type: EXPERIMENTAL
Intervention: AD + MTHFR polymorphisms
Number of subjects: 243
Study 35001885 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-Prenatal Screening Period fetal losses (CP + BO + gw ≤ 10 fetal losses + EP + TD) in AD
Number of subjects: 243
Study 35001885 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-Prenatal Screening Period fetal losses (CP + BO + gw ≤ 10 fetal losses + EP + TD) in MTHFR
Number of subjects: 243
Study 35001885 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-Prenatal Screening Period fetal losses (CP + BO + gw ≤ 10 fetal losses + EP + TD) in AD + MTHFR
Number of subjects: 243
Study 35001885 — intervention group
Group type: COMPARATOR
Intervention: Gravidity ⩽ 4
Number of subjects: 243
Study 32949500 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical Pyo bacteriophage (Pyophage; 20 mL)
Number of subjects: 113
Study 32949500 — intervention group
Group type: COMPARATOR
Intervention: Intravesical placebo solution (20 mL)
Number of subjects: 113
Study 32949500 — intervention group
Group type: COMPARATOR
Intervention: Systemically applied antibiotics
Number of subjects: 113
Study 35803754 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral single‐injection erector spinae plane block (ESPB) with ropivacaine 0.5%, 15 ml on each side
Number of subjects: 50
Study 35803754 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral single‐injection erector spinae plane block (ESPB)
Number of subjects: 50
Study 35803754 — intervention group
Group type: COMPARATOR
Intervention: Patient‐controlled intravenous analgesia
Number of subjects: 50
Study 33966019 — intervention group
Group type: COMPARATOR
Intervention: Saline colloid (6% hydroxyethyl starch 130/0.4 in 0.9% NaCl)
Number of subjects: 88
Study 33966019 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced colloid (6% hydroxyethyl starch 130/0.4 in an isotonic solution)
Number of subjects: 88
Study 35287561 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocked practice
Number of subjects: 10
Study 35287561 — intervention group
Group type: EXPERIMENTAL
Intervention: Random practice
Number of subjects: 10
Study 32969548 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (aRT) administered on the tumour bed and pelvis within 6 months of RP.
Number of subjects: 187
Study 32697031 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief cognitive-behavioural therapy (CBT-T)
Number of subjects: 193
Study 32697031 — intervention group
Group type: COMPARATOR
Intervention: Standard cognitive-behavioural therapy (20 sessions)
Number of subjects: 193
Study 34461038 — intervention group
Group type: EXPERIMENTAL
Intervention: Spore-forming probiotics
Number of subjects: 13
Study 34461038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 32826769 — intervention group
Group type: EXPERIMENTAL
Intervention: Netarsudil 0.02% once-daily
Number of subjects: 839
Study 32826769 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5% twice-daily
Number of subjects: 839
Study 34035106 — intervention group
Group type: EXPERIMENTAL
Intervention: Bougie
Number of subjects: 1106
Study 34035106 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal tube with stylet
Number of subjects: 1106
Study 33389912 — intervention group
Group type: EXPERIMENTAL
Intervention: L-PRF application in extraction socket
Number of subjects: 22
Study 33389912 — intervention group
Group type: COMPARATOR
Intervention: No material (control) in contralateral socket
Number of subjects: 22
Study 34363816 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat
Number of subjects: 16
Study 34363816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 33577770 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (CGM)
Number of subjects: 182
Study 33577770 — intervention group
Group type: COMPARATOR
Intervention: Standard care (with masked CGM)
Number of subjects: 182
Study 33141262 — intervention group
Group type: EXPERIMENTAL
Intervention: BREATHLESSALL protocol (breathlessness sensory intensity, breathlessness unpleasantness, work/effort of breathing, unsatisfied inspiration)
Number of subjects: 15
Study 33141262 — intervention group
Group type: EXPERIMENTAL
Intervention: SI+UN protocol
Number of subjects: 15
Study 33141262 — intervention group
Group type: EXPERIMENTAL
Intervention: SI alone protocol
Number of subjects: 15
Study 36162522 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week cardiac rehabilitation program
Number of subjects: 41
Study 33740347 — intervention group
Group type: EXPERIMENTAL
Intervention: Transverse puncture method
Number of subjects: 57
Study 33740347 — intervention group
Group type: COMPARATOR
Intervention: Vertical puncture method
Number of subjects: 57
Study 33740347 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 57
Study 32370061 — intervention group
Group type: EXPERIMENTAL
Intervention: TB NecP
Number of subjects: 20
Study 32370061 — intervention group
Group type: EXPERIMENTAL
Intervention: TB TP
Number of subjects: 20
Study 32370061 — intervention group
Group type: EXPERIMENTAL
Intervention: TB EOL
Number of subjects: 20
Study 32370061 — intervention group
Group type: COMPARATOR
Intervention: RG
Number of subjects: 20
Study 34915492 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab, 5-fluorouracil, cisplatin, and Docetaxel (D)
Number of subjects: 180
Study 34915492 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab, 5-fluorouracil, and cisplatin (C)
Number of subjects: 180
Study 34915492 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms (with and without Docetaxel)
Number of subjects: 180
Study 34116249 — intervention group
Group type: EXPERIMENTAL
Intervention: G2 - 35% carbamide peroxide (CP) and violet LED
Number of subjects: 20
Study 34116249 — intervention group
Group type: EXPERIMENTAL
Intervention: G4 - 35% hydrogen peroxide (HP)
Number of subjects: 20
Study 34116249 — intervention group
Group type: COMPARATOR
Intervention: G1 - violet LED
Number of subjects: 20
Study 34116249 — intervention group
Group type: COMPARATOR
Intervention: G3 - only CP 35%
Number of subjects: 20
Study 34116249 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 20
Study 32725972 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted radical cystectomy (RARC)
Number of subjects: 110
Study 32725972 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic radical cystectomy (LRC)
Number of subjects: 110
Study 35404709 — intervention group
Group type: EXPERIMENTAL
Intervention: Calisthenic exercise program via telerehabilitation
Number of subjects: 255
Study 35404709 — intervention group
Group type: COMPARATOR
Intervention: Control group (no formal exercise training)
Number of subjects: 255
Study 89120227 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral testosterone treatment
Number of subjects: 0
Study 89120227 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 36442498 — intervention group
Group type: EXPERIMENTAL
Intervention: Vi polysaccharide‐tetanus toxoid conjugate vaccine (Vi‐TT)
Number of subjects: 27882
Study 33591006 — intervention group
Group type: EXPERIMENTAL
Intervention: EA‐230 (90 mg/kg/hr)
Number of subjects: 180
Study 33591006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 34779583 — intervention group
Group type: EXPERIMENTAL
Intervention: LYT‐100 (deupirfenidone) 100 mg twice daily
Number of subjects: 0
Study 34779583 — intervention group
Group type: EXPERIMENTAL
Intervention: LYT‐100 (deupirfenidone) 250 mg twice daily
Number of subjects: 0
Study 34779583 — intervention group
Group type: EXPERIMENTAL
Intervention: LYT‐100 (deupirfenidone) 500 mg twice daily
Number of subjects: 0
Study 34779583 — intervention group
Group type: EXPERIMENTAL
Intervention: LYT‐100 (deupirfenidone) 750 mg twice daily
Number of subjects: 0
Study 34779583 — intervention group
Group type: EXPERIMENTAL
Intervention: LYT‐100 (deupirfenidone) 1000 mg twice daily
Number of subjects: 0
Study 34779583 — intervention group
Group type: EXPERIMENTAL
Intervention: LYT‐100 (deupirfenidone) 500 mg single dose (fed condition)
Number of subjects: 0
Study 34779583 — intervention group
Group type: EXPERIMENTAL
Intervention: LYT‐100 (deupirfenidone) 500 mg single dose (fasting condition)
Number of subjects: 0
Study 34779583 — intervention group
Group type: EXPERIMENTAL
Intervention: LYT‐100 (deupirfenidone) up to 1000 mg twice daily
Number of subjects: 0
Study 34779583 — intervention group
Group type: EXPERIMENTAL
Intervention: LYT‐100 (deupirfenidone)
Number of subjects: 0
Study 35390321 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive warming to a target core temperature of 37°C
Number of subjects: 5013
Study 35390321 — intervention group
Group type: COMPARATOR
Intervention: Routine thermal management to a target of 35.5°C
Number of subjects: 5013
Study 35390321 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive warming
Number of subjects: 5013
Study 35390321 — intervention group
Group type: COMPARATOR
Intervention: Routine thermal management
Number of subjects: 5013
Study 33781703 — intervention group
Group type: EXPERIMENTAL
Intervention: iTBS-γ tACS
Number of subjects: 40
Study 33781703 — intervention group
Group type: COMPARATOR
Intervention: iTBS-sham tACS
Number of subjects: 40
Study 33781703 — intervention group
Group type: EXPERIMENTAL
Intervention: γ-tACS alone
Number of subjects: 40
Study 36409753 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise utilizing a balance disc and smartphone inclinometer application
Number of subjects: 32
Study 36409753 — intervention group
Group type: COMPARATOR
Intervention: Traditional therapy (Control)
Number of subjects: 32
Study 32193992 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with a specific intervention (not specified)
Number of subjects: 0
Study 32193992 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold linear mixed model
Number of subjects: 0
Study 32193992 — intervention group
Group type: EXPERIMENTAL
Intervention: Broyden‐Fletcher‐Goldfarb‐Shanno algorithm
Number of subjects: 0
Study 34840031 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment + AFO-202 beta glucan (n=8)
Number of subjects: 24
Study 34840031 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment + combination of AFO-202 and N-163 beta glucans (n=8)
Number of subjects: 24
Study 34840031 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control group, n=8)
Number of subjects: 24
Study 32831151 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenfu injection (100 ml, twice a day for 7 days)
Number of subjects: 300
Study 32831151 — intervention group
Group type: COMPARATOR
Intervention: Saline (identical volume, twice a day for 7 days)
Number of subjects: 300
Study 32831151 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenfu injection
Number of subjects: 300
Study 32831151 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 300
Study 34929690 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed care bundle (early intensive blood pressure lowering, glycaemic control, treatment of pyrexia, and reversal of anticoagulation)
Number of subjects: 0
Study 34929690 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 33277289 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression garment on top of usual care (information and exercises)
Number of subjects: 0
Study 33277289 — intervention group
Group type: COMPARATOR
Intervention: Usual care (information and exercises)
Number of subjects: 0
Study 36202236 — intervention group
Group type: COMPARATOR
Intervention: Standard message group
Number of subjects: 1235
Study 36202236 — intervention group
Group type: COMPARATOR
Intervention: COVID-19 vaccine message group
Number of subjects: 1235
Study 34459398 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE+ PRS
Number of subjects: 6244
Study 34459398 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D‐binding protein (protein PRS APOE‐)
Number of subjects: 6244
Study 34459398 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin‐like growth factor‐binding protein 2 (AD APOE‐ PRS)
Number of subjects: 6244
Study 34459398 — intervention group
Group type: COMPARATOR
Intervention: Bi-directional MR for five proteins
Number of subjects: 6244
Study 32998649 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone call intervention delivered by nurses (up to 16 calls, mean duration = 12 minutes)
Number of subjects: 60
Study 32998649 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone call intervention delivered by nurses
Number of subjects: 60
Study 32998649 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 60
Study 35830313 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular incision subperiosteal tunneling access (VISTA) with acellular dermal matrix (ADM) grafts
Number of subjects: 9
Study 35830313 — intervention group
Group type: COMPARATOR
Intervention: Sulcular tunnel access (STA) with acellular dermal matrix (ADM) grafts
Number of subjects: 9
Study 33039390 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for pelvic organ prolapse
Number of subjects: 1250
Study 33039390 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomic failure
Number of subjects: 1250
Study 33039390 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective failure
Number of subjects: 1250
Study 33039390 — intervention group
Group type: EXPERIMENTAL
Intervention: Retreatment for pelvic organ prolapse
Number of subjects: 1250